Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen

NCT00484276 is registered in ClinicalTrials.gov with AGC Biologics S.p.A. as lead sponsor.

NCT NCT00484276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00484276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen
Lead sponsor
AGC Biologics S.p.A.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
March 31, 2013
Enrollment
57 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma